Ted Fjällman
Partner @ Flerie Invest
London, United Kingdom
Ted Fjällman is a Chief Executive Officer at NorthX Biologics. He Attended London Business School.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Ted Fjällman invests in
Stages Ted Fjällman invests in
Countries Ted Fjällman invests in
Investment Focus
Industry
- Health Care 2 (40%)
- Therapeutics 2 (40%)
- Biotechnology 2 (40%)
- Pharmaceutical 2 (40%)
Stage
- Series A 2 (40%)
- Funding Round 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- Sweden 1 (20%)
- United States 1 (20%)
- The Netherlands 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Synerkine Pharma
|
Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models. | $5.6M / Series A / Oct 12, 2023 | |
XNK Therapeutics
|
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. Thecompany's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden | $12.7M / Mar 29, 2022 | |
|
XNK Therapeutics
|
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. Thecompany's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden | $14.2M / Venture - Series Unknown / Mar 29, 2022 | |
Geneos Therapeutics
|
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $17M / Series A / Mar 24, 2022 | |
|
Synerkine Pharma
|
Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models. | $4M / Series A / Dec 16, 2021 |
Co-Investors
Thuja Capital
2 deals together
Global Bio Fund
1 deal together
InnovationQuarter
1 deal together
Inovio Pharmaceuticals
1 deal together
Korea Investment Partners
1 deal together
Sante Ventures
1 deal together
About Flerie Invest
Flerie Invest is a Europian investment firm that makes investments in the health care sector companies.
Flerie Invest Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Thomas Eldered
Executive Chairman
|
|||
|
Ted Fjällman
Partner
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ted Fjällman invest in?
Ted Fjällman invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 5 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ted Fjällman last invest?
The most recent investment recorded for Ted Fjällman closed in Oct 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
